A Canadian patient has taken legal action regarding diabetes drug Invokana. Find out the Johnson & Johnson subsidiary that manufactures Invokana and Invokamet (a combination drug with older diabetes drug metformin). November 16, 2017 – Wrongful Death Suit Filed Over Diabetes Drug Invokana.
The FDA was forced to issue two major safety alerts regarding the widely-prescribed drug in 2015 alone. 2017 saw yet another huge revelation, as researchers at the federal agency confirmed a causal link between Invokana and an increased risk in lower limb amputations. Currently, these required safety studies are still in progress, but consumers are already falling victim to serious ailments that may have been caused by Invokana.
In forming product liability suits, attorneys typically focus on any failures in safely formulating and manufacturing the drug of interest as well as on inaccuracies from product advertisements and labels.
Damages listed in lawsuits involving a wrongful death include expenses and financial losses related to the death, such as any relevant medical costs, funeral expenses, and loss of spousal support.
They released a statement that patients that use these drugs should “check their feet regularly and follow their doctor’s advice on routine preventative foot care.” A new warning will be included in the prescribing information for SGLT2 Inhibitors which will list lower limb amputation as an uncommon side effect.
Invokana Lawsuit. Invokana lawsuits claim that Johnson & Johnson failed to warn of diabetic ketoacidosis (DKA), kidney problems, pancreatitis, bone fractures, and cardiovascular side effects.. In May 2017, the FDA ordered a black box warning (the highest warning it can issue) for the risk of toe, foot, and leg amputations.
Symptoms of ketoacidosis, as noted by the American Diabetes Association, include:
Those who may be eligible for an Invokana lawsuit should contact us for a free, no-obligation case review. There are no costs unless we win an award or settlement.
Adverse renal functions associated with these drugs include:. Adverse event data has also pointed to possible impaired kidney function caused by Invokana and similar drugs.
There was particular concern about one clinical study that showed 13 cardiovascular (CV) events in the Invokana group, compared to just one CV event in the placebo group.
NEW YORK, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Endo International plc (“Endo” or the “Company”) (NASDAQ:ENDP) and certain of its officers. The class action, filed in United States District Court, for the Eastern District of.
Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. See www.pomerantzlaw.com. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.
The type 2 diabetes drug Invokamet (generic: canagliflozin/metformin) has been linked to an increased risk for serious side effects including diabetic ketoacidosis (DKA), kidney failure, heart attack, bone fractures and amputations. You may be entitled to compensation by filing a class action suit and our lawyers can help.
With this expanded approval, Invokamet may now be prescribed to type 2 diabetes patients who are not already being treated with canagliflozin or metformin, and may benefit from dual therapy. May 24, 2016 – Janssen announced today that the FDA has approved Invokamet as a first-line treatment for adults with type 2 diabetes, according to Street Insider.
2750, according to a Pretrial Order issued last week. March 30, 2017 – A Common Benefit Fee and Expense Fund has been established in the Invokana MDL “to provide for the fair and equitable sharing among plaintiffs and their counsel” for expenses incurred during the litigation process.
The diabetes drug metformin may interfere with cognitive abilities, according to the findings of a new study.
Eileen Moore, PhD, and her team of researchers from the University of Melbourne in Australia used a mini-mental state exam (MMSE) to determine cognitive performance in patients. The average patients age was 73 years old, with approximay 60% being female.
Tags: Diabetes, Diabetes Drug, Fortamet, Glucophage, Glumetza, Janumet, Merck, Metformin, Riomet.
More than 1,300 patients were evaluated who had Alzheimer’s disease, mildly impaired brain function and no cognitive impairments; along with a subset group which also had type 2 diabetes or impaired glucose intolerance.